ProPharma Honored with 2024 CRO Leadership Award

ProPharma, the world’s largest research consulting organization (RCO), a leading global provider of regulatory, clinical, and compliance services for the life sciences industry is pleased to announce it received a 2024 CRO Leadership Award.

Uppsala University Hospital chooses AI-based Qlucore Insights to develop precision diagnostics

Please see latest news from Qlucore who has signed an agreement with Uppsala University Hospital. The Hospital will use the Qlucore Insights software to improve the analysis of acute lymphoblastic leukemia (ALL) in children. Please get in touch if you require further information.

New Research Illustrates How to Drive Earlier Diagnosis and Treatment of Kidney Disease

A new survey by Phreesia, in partnership with the National Kidney Foundation, finds that discussions between patients and providers, and patient activation, are key to helping high-risk patients take preventive actions to manage their kidney health.

Onyx Scientific Aims for European Growth with New BD Hire

Small molecule specialists Onyx Scientific has made a significant new addition to its commercial team with the appointment of Courtnie Thomas Wilks as Business Development Manager for the UK and Europe.

MIB Agents’ Community of Families Has Awarded Over $1.9M in Grants to Research Pediatric Bone Cancer

Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

Mage Biologics (“Mage”) announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for the treatment of inflammatory bowel disease (IBD).

Integrated DNA Technologies Announces New Primers and Probe Set to Identify H5N1 Avian Influenza

Integrated DNA Technologies today launched the Avian Influenza Type A (H5) Primers and Probe Set to enable researchers to identify, target, and trace the presence of clade 2.3.4.4b of the H5N1 virus across bird, environmental, dairy cow, and poultry farm samples.

CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT

CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT

CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’

CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’ CluePoints extends its use of AI/ML and continues to find smarter ways to manage clinical trials

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

Exothera has announced that Asgard Therapeutics has selected them to develop and scale-up a manufacturing process for the viral vector-based immunotherapy candidate AT-108, including development of analytical methods, GMP-grade material production, and aseptic filling.

CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation

FDA and CluePoints Sign New 3 Year Cooperative Research and Development Agreement to Assess Data Quality using Statistical Modelling and Machine Learning

FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials

City University of New York Partners with Genestack to Enhance AI readiness of Life Science Data in the Bioconductor Program

Genestack has announced a collaboration with City University of New York (CUNY) to streamline data curation for the BioConductor program, a widely used open-source software project that provides tools for the analysis and comprehension of high-throughput genomic data.

Syngene launches platform for rapid, enhanced protein production

Sinequa Augments Companies with Release of New Generative AI Assistants

Sinequa announces new AI Assistants; Combining Sinequa’s Search with GenAI provides the ultimate AI Assistant and virtual coworker

The varvis® Software: The First Genomics End-to-End Software Certified as IVDR Class C Device

We are pleased to announce that Limbus Medical Technologies GmbH, a medical device manufacturer and software development company based in Rostock, Germany, has reached a significant milestone in the field of genetic diagnostics. The varvis® software is now the first complete genomics software solution certified as a Class C device under the In-Vitro Diagnostic Regulation (IVDR) EU 2017/746.

Qlucore starts project after receiving prestigious EU grant to advance personalized cancer treatment

Qlucore to receive a prestigious EIC Accelerator grant of 2,5 million Euros to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer.

4D Path Announces New Data Highlighting Efficacy of the Q-plasia OncoReader (QPOR) Platform

We wanted to reach out today with some exciting, breaking news. 4D Path, a company dedicated to personalizing cancer care through their advanced approach to predicting tumor response announced this morning new clinical data regarding the efficacy of their patented Q-Plasia OncoReader (QPOR) platform, highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. "This is an exciting moment for oncology and pathology," said Stuart J. Schnitt, M.D., Chief of Breast Oncologic Pathology for the Dana-Farber Brigham Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Program. "The 4D Path QPOR Platform can potentially help inform researchers and clinicians about which patients are more or less likely to respond to neoadjuvant chemotherapy, paving the path for more precise and personalized treatments for patients." For the first time ever, we can unveil the dynamics of the tumor microenvironment, allowing biopharma and clinicians to get more targeted and precise in the development of therapies and treatment plans. Not only that, but the profound effects this will have on clinical trials and patient stratification, the benefits to pathologists and clinicians on the front lines with patients, and to patients – not only getting more targeted treatments but also helping the people who would have not responded, more effectively get to a treatment plan that might work. This is a monumental step forward in oncology. We would love to connect you with Satabhisa Mukhopadhyay, PHD, Chief Scientific Officer and Co-Founder of 4D Path, to provide more commentary regarding the importance of this moment and how their innovative, human approach (no AI, no machine learning) is allowing us to be more effective and specific when developing and implementing treatments. We would also be happy to discuss submitting an article authored by Satabhisa discussing these topics, and connect you with industry experts like Dr. Schnitt as well. We have placed below the press release for your reference. Please let us know if you have any questions. We are always available. Look forward to hearing from you.

AES Clean Technology Announces Appointment of New CEO

PathAI Expands Portfolio of AI-Powered Products, Announcing PathExplore™ IOP and IHC Explore™ Ahead of ASCO 2024

PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™ to empower cancer drug developers and clinical researchers with AI-powered insights. The product pairing provides unprecedented single-cell and spatial resolution of the tumor microenvironment from routine pathology samples to facilitate biomarker discovery and deeper understanding of treatment response for the next generation of cancer therapeutics. The expansion of the Explore™ portfolio comes at a time when AI-pathology is experiencing accelerated large-scale adoption across the diagnostic and biopharma industries.